(1R,5S)-N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-3-[3,3-dimethyl-2(S)-[[[[2-methyl-1(R)-(phenylmethyl)propyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide | 864809-08-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (1R,5S)-N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-3-[3,3-dimethyl-2(S)-[[[[2-methyl-1(R)-(phenylmethyl)propyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
• 英文别名: (1R,2S,5S)-N-(4-amino-1-cyclopropyl-3,4-dioxobutan-2-yl)-3-[(2S)-3,3-dimethyl-2-[[(2R)-3-methyl-1-phenylbutan-2-yl]carbamoylamino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• CAS: 864809-08-5
• 化学式: C₃₃H₄₉N₅O₅
• 分子量: 595.783
• InChiKey: VSIOQSQMFWTZBT-HREBWTLMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  43
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  151
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (1R,2S,5S)-N-(4-amino-1-cyclopropyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-amino-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;hydrochloride 、 [(2R)-2-isocyanato-3-methylbutyl]benzene 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (1R,5S)-N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-3-[3,3-dimethyl-2(S)-[[[[2-methyl-1(R)-(phenylmethyl)propyl]amino]carbonyl]amino]-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
  参考文献：
  名称：

  Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P₄-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic Profiles

  摘要：

  Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) were encouraging, and thus, additional human clinical studies are underway. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P-4 pocket and optimization of the P-1' capping led to the discovery of new ketoamide inhibitors of the HCV NS3 serine protease with improved in vitro potency. In addition to being potent inhibitors of HCV subgenomic RNA replication, some of the new P-4-capped inhibitors were also found to have improved PK profile.

  DOI：

  10.1021/jm801632a

文献信息

• Novel inhibitors of Hepatitis C virus NS3 protease
  申请人：Bogen L. Stephane

  公开号：US20070142301A1

  公开（公告）日：2007-06-21

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
• US7205330B2
  申请人：——

  公开号：US7205330B2

  公开（公告）日：2007-04-17
• US7423058B2
  申请人：——

  公开号：US7423058B2

  公开（公告）日：2008-09-09
• Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P₄-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic Profiles
  作者：Stéphane L. Bogen、Weidong Pan、Sumei Ruan、Latha G. Nair、Ashok Arasappan、Frank Bennett、Kevin X. Chen、Edwin Jao、Srikanth Venkatraman、Bancha Vibulbhan、Rong Liu、Kuo-Chi Cheng、Zhuyan Guo、Xiao Tong、Anil K. Saksena、Viyyoor Girijavallabhan、F. George Njoroge

  DOI：10.1021/jm801632a

  日期：2009.6.25

  Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) were encouraging, and thus, additional human clinical studies are underway. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P-4 pocket and optimization of the P-1' capping led to the discovery of new ketoamide inhibitors of the HCV NS3 serine protease with improved in vitro potency. In addition to being potent inhibitors of HCV subgenomic RNA replication, some of the new P-4-capped inhibitors were also found to have improved PK profile.